Back to User profile » Dr Tsung-Ying Yang
Papers published by Dr Tsung-Ying Yang:
Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy
Ou WF, Liao PY, Hsu YW, Huang YH, Hsu KH, Tseng JS, Chang GC, Yang TY
Cancer Management and Research 2023, 15:1251-1262
Published Date: 6 November 2023
The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
Chen KC, Huang YH, Hsu KH, Tseng JS, Chang GC, Yang TY
OncoTargets and Therapy 2023, 16:317-326
Published Date: 17 May 2023
Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
Hsu KH, Huang JW, Tseng JS, Chen KW, Weng YC, Yu SL, Yang TY, Huang YH, Chen JJW, Chen KC, Chang GC
OncoTargets and Therapy 2021, 14:2139-2148
Published Date: 25 March 2021
Tissue transglutaminase 2 expression is epigenetically regulated in human lung cancer cells and prevents reactive oxygen species-induced apoptosis
Lee MY, Wu MF, Cherng SH, Chiu LY, Yang TY, Sheu GT
Cancer Management and Research 2018, 10:2835-2848
Published Date: 23 August 2018
Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
Tseng JS, Yang TY, Chen KC, Hsu KH, Yu CJ, Liao WY, Tsai CR, Tsai MH, Yu SL, Su KY, Chen JJ, Chen HY, Chang GC
OncoTargets and Therapy 2014, 7:799-805
Published Date: 23 May 2014